Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Earnings and Valuation
This table compares Connect Biopharma and Pyxis Oncology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Connect Biopharma | $2.95 million | 13.40 | -$55.48 million | ($1.14) | -0.55 |
| Pyxis Oncology | $11.04 million | 18.20 | -$79.62 million | ($1.30) | -1.29 |
Connect Biopharma has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by company insiders. Comparatively, 10.5% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Connect Biopharma has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Profitability
This table compares Connect Biopharma and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -182.86% | -127.70% |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Connect Biopharma and Pyxis Oncology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
Connect Biopharma currently has a consensus price target of $5.88, indicating a potential upside of 835.21%. Pyxis Oncology has a consensus price target of $8.71, indicating a potential upside of 418.71%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Pyxis Oncology.
Summary
Connect Biopharma beats Pyxis Oncology on 9 of the 13 factors compared between the two stocks.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
